Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.

Abstract

BACKGROUND:

We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy.

METHODS:

The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated.

RESULTS:

The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240-3360 mg), and the median 1M-RDI was 61.9% (7.1%-100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08-0.48, p = 0.0004 and HR 0.2, 95% CI 0.08-0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06-0.55, p = 0.002) and hand-foot skin reaction (HR 0.03, 95% CI 0.008-0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression.

CONCLUSION:

A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice.

• Authors: Wan Wang, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Kento Inada, Sakura Kirino, Koji Yamashita, Shuhei Sekiguchi, Yuka Hayakawa, Leona Osawa, Mao Okada, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi
• Journal: Cancers (Cancers (Basel)) Vol. 11 Issue 10 (Oct 09 2019) ISSN: 2072-6694 [Print] Switzerland
• PMID: 31601010 (Publication Type: Journal Article)